The novel self-expanding bioprosthetic ACURATE neo valve did not demonstrate noninferiority to the currently available CoreValve Evolute valve in patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), according to the SCOPE* II trial.
Durable polymer drug-eluting stents (DES) appeared noninferior to biodegradable polymer DES in patients with acute coronary syndrome (ACS) with stenosis scheduled for percutaneous coronary intervention (PCI), results of the Korea-based HOST-Reduce-Polytech-ACS* trial showed. However, the device-oriented outcome appeared to side with the durable stent.
Patients with vulnerable plaques have a significantly greater risk of major adverse cardiovascular events (MACE), but prophylactic PCI* of these non-flow-limiting lipid-rich plaques substantially expands the lumen area, which may prevent future clinical events, according to the PROSPECT II and PROSPECT ABSORB studies presented at TCT 2020.
Giving crushed prasugrel to patients with ST-segment elevation myocardial infarction (STEMI) en route to the hospital for planned PCI* does not improve reperfusion rates compared with giving the tablets whole in the COMPARE CRUSH trial.
Patients with ST-elevation and COVID-19 have different characteristics than those without COVID-19, and may have a higher risk of in-hospital mortality and stroke, according to initial results of the NACMI* registry study presented at TCT Connect 2020.
The use of paclitaxel drug-coated devices did not appear to affect mortality risk in patients with symptomatic peripheral artery disease (PAD) who underwent endovascular lower extremity revascularization, according to subgroup analysis of the VOYAGER PAD* trial.
A daily, 4-gram dose of icosapent ethyl (IPE) led to a significant reduction in ischaemic events in a subgroup of patients from the REDUCE-IT* cohort who had prior PCI**, according to the prespecified analysis of the REDUCE-IT PCI trial presented at TCT 2020.
In select patients with advanced heart failure (HF), use of MitraClip as bridge therapy to heart transplantation appeared to be a promising strategy to reduce worsening and progression of underlying disease while awaiting transplant, suggests the MitraBridge study, even implying that post-procedural improvements may drive the removal of patients from the transplant list.
In patients with critical limb ischaemia (CLI) due to chronic total occlusions in the infrapopliteal region, drug-coated balloon (DCB) angioplasty was associated with a lower rate of late lumen loss compared with the standard balloon angioplasty – percutaneous transluminal angioplasty (PTA), according to the results of the IN.PACT below-the-knee (BTK) feasibility study presented at TCT 2020.
Treatment with dual antiplatelet therapy (DAPT) after PCI* can safely be shortened to 1 or 3 months without raising ischaemic risk in select patients with high bleeding risk, according to the XIENCE 90/28 trials presented at TCT 2020.